{"id":3435,"date":"2025-11-12T16:27:10","date_gmt":"2025-11-12T16:27:10","guid":{"rendered":"https:\/\/greathealthgreatfitness.com\/?p=3435"},"modified":"2025-11-12T16:27:12","modified_gmt":"2025-11-12T16:27:12","slug":"experimental-drug-lepodisiran-marks-major-breakthrough-in-genetic-heart-disease-risk","status":"publish","type":"post","link":"https:\/\/greathealthgreatfitness.com\/index.php\/2025\/11\/12\/experimental-drug-lepodisiran-marks-major-breakthrough-in-genetic-heart-disease-risk\/","title":{"rendered":"Experimental Drug Lepodisiran Marks Major Breakthrough in Genetic Heart-Disease Risk"},"content":{"rendered":"\n

A single dose reduces lipoprotein(a) by over 90% in large international trial<\/em><\/p>\n\n\n\n

In a landmark development for cardiovascular medicine, the experimental gene-silencing drug Lepodisiran has delivered dramatic reductions in a genetically-driven heart risk factor known as lipoprotein(a) or \u201cLp(a)\u201d\u2014a target long considered untreatable.
What is Lp(a) and why it matters<\/p>\n\n\n\n

Lipoprotein(a) is a cholesterol-like particle produced by the liver, found in approximately one in five people worldwide in elevated levels. Unlike standard LDL cholesterol, Lp(a) is far less affected by diet or exercise, and is strongly genetically determined. High Lp(a) levels contribute to arterial plaque buildup and raise risks of heart attack, stroke and aortic stenosis.Until now, no approved therapies existed specifically to lower Lp(a).
Trial data and scope<\/p>\n\n\n\n

In a Phase 2 trial led by the Cleveland Clinic, over 300 patients were enrolled across multiple countries (including the United States, Argentina, China, Germany, Japan and Spain) with a mean age of 62. Participants received a single 400 mg dose of Lepodisiran and were followed up to 540 days. The results? Lp(a) levels dropped by 93.9% from day 60 to day 180 after one dose. Even at 540 days post-dose, levels remained 53% below baseline. Another trial using a different siRNA therapy (Zerlasiran) found reductions of more than 80%. <\/p>\n\n\n\n

Safety data to date have been favourable: no major safety signals have emerged. Some injection-site reactions occurred (up to 10% of participants), but no serious adverse events linked to the drug were reported in the primary analyses. <\/p>\n\n\n\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n